1 GBD 2015 Mor t al i t y and Cause s of De ath

Collaborators. Global，regional，and national life

expectancy，all-cause mortality，and cause-specific

mortality for 249 causes of death，1980-2015：a

systematic analysis for the Global Burden of Disease

Study 2015[J]. Lancet，2016，388：1459-1544.

2 Feigin VL，Roth GA，Naghavi M，et al. Global

Burden of Diseases，Injuries and Risk Factors Study

2013 and Stroke Experts Writing Group. Global

burden of stroke and risk factors in 188 countries，

during 1990-2013：a systematic analysis for the Global

Burden of Disease Study 2013[J]. Lancet Neurol，

2016，15：913-924.

3 Satizabal CL，Beiser AS，Chouraki V，et al. Incidence

of dementia over three decades in the Framingham

Heart Study[J]. N Engl J Med，2016，374：523-532.

4 Lyall DM，Celis-Morales CA，Anderson J，et

al. Associat ions between single and mult iple

cardiometabolic diseases and cognitive abilities in 474

129 UK Biobank participants[J]. Eur Heart J，2016-11-

15[Epub ahead of print].

5 Tosto G，Bird TD，Bennett DA，et al. National

Institute on Aging Late-Onset Alzheimer Disease/

National Cell Repository for Alzheimer Disease

(NIA-LOAD/NCRAD) Family Study Group. The role

of cardiovascular risk factors and stroke in familial

Alzheimer disease[J]. JAMA Neurol，2016，73：1231-

1237.

6 Amarenco P，Lavallée PC，Labreuche J，et al.

TIAregistry. org Investigators. One-Year Risk of

Stroke after Transient Ischemic Attack or Minor

Stroke[J]. N Engl J Med，2016，374：1533-1542.

7 Yaghi S，Rostanski SK，Boehme AK，et al. Imaging

parameters and recurrent cerebrovascular events

in patients with minor stroke or transient ischemic

attack[J]. JAMA Neurol，2016，73：572-578.

8 Nasr DM，Brown RD. The challenges of stroke

prediction scores[J]. JAMA Neurol，2016，73：510-511.

9 Kelly PJ，Albers GW，Chatzikonstantinou A，et al.

Validation and comparison of imaging-based scores

for prediction of early stroke risk after transient

ischaemic attack：a pooled analysis of individualpatient

data from cohort studies[J]. Lancet Neurol，

2016，15：1238-1247.

10 Anderson CS，Robinson T，Lindley RI，et al.

ENCHANTED Investigators and Coordinators. Lowdose

versus standard-dose intravenous alteplase in

acute ischemic stroke[J]. N Engl J Med，2016，374：

2313-2323.

11 Aoki J，Kimura K. Stroke：The question of alteplase

dose for stroke is not resolved[J]. Nat Rev Neurol，

2016，12：376-377.

12 Strbian D，Saposnik G. Review of the ENCHANTED

Tr ial (Enhanced Cont rol of Hyper tension and

Thrombolysis Stroke Study). How low can we go with

intravenous tissue-type plasminogen activator dose

and blood pressure level?[J]. Stroke，2016，47：3063-

3064.

13 Rosenfield K，Matsumura JS，Chaturvedi S，et al.

ACT I Investigators. Randomized Trial of Stent versus

Surgery for Asymptomatic Carotid Stenosis[J]. N

Engl J Med，2016，374：1011-1020.

14 Brott TG，Howard G，Roubin GS，et al. Long-term

results of Stenting versus Endarterectomy for Carotid-

Artery Stenosis[J]. N Engl J Med，2016，374：1021-

1031.

15 Bissacco D. Carotid artery stenosis：The curse of best

medical therapy[J]. Angiology，2017，68：87-88.

16 Johnston SC，Amarenco P，Albers GW，et al.

SOCRATES Steering Committee and Investigators.

Ticagrelor versus Aspirin in Acute Stroke or Transient

Ischemic Attack[J]. N Engl J Med，2016，375：35-43.

17 Wang Y，Minematsu K，Wong KS，et al. SOCRATES

Steering Committee and Investigators. Ticagrelor

in acute stroke or transient ischemic attack in Asian

patients：From the SOCRATES Trial (Acute Stroke

or Transient Ischemic Attack Treated With Aspirin or

Ticagrelor and Patient Outcomes)[J]. Stroke，2017，48：

167-173.

18 Hiatt WR，Fowkes FG，Heizer G，et al. EUCLID

Trial Steering Committee and Investigators. Ticagrelor

versus Clopidogrel in Symptomatic Peripheral Artery

Disease[J]. N Engl J Med，2016-11-13[Epub ahead of

print].

19 Wang Y，Zhao X，Lin J，et al. Association between

CYP2C19 loss-of-function allele status and efficacy

of clopidogrel for risk reduction among patients with

minor stroke or transient ischemic attack[J]. JAMA，

2016，316：70-78.

20 Pan Y，Chen W，Xu Y，et al. Genetic polymorphisms

and clopidogrel efficacy for acute ischemic stroke or

transient ischemic attack：A systematic review and

Meta-analysis[J]. Circulation，2017，135：21-33.

21 Simon T，Danchin N. Clinical impact of pharmacogenomics

of clopidogrel in stroke[J]. Circulation，2017，

135：34-37.

22 Kernan WN，Viscoli CM，Furie KL，et al. Pioglitazone

after ischemic stroke or transient ischemic attack[J]. N

Engl J Med，2016，374：1321-1331.

23 I n z u c ch i SE，Vi s col i CM，Young LH，e t a l .

Pioglitazone prevents diabetes in patients with insulin

resistance and cerebrovascular disease[J]. Diabetes

Care，2016，39：1684-1692.

24 Lee M，Saver JL，Liao HW，et al. Pioglitazone for

secondary stroke prevention：A systematic review and

Meta-analysis[J]. Stroke，2016-11-20[Epub ahead of

print].

25 Qureshi AI，Palesch YY，Barsan WG，et al. Intensive

blood-pressure lowering in patients with acute

cerebral hemorrhage[J]. N Engl J Med，2016，375：

1033-1043.